# Allogene Therapeutics Inc. (ALLO) — Operating Income

## Annual Operating Income (USD)

| Year | Operating Income |
| --- | --- |
| 2025 | -$209M |
| 2024 | -$273M |
| 2023 | -$328M |
| 2022 | -$336M |
| 2021 | -$180M |
| 2020 | -$258M |
| 2019 | -$202M |

## Quarterly Operating Income (USD)

| Quarter | Operating Income |
| --- | --- |
| 2025-09-30 | -$45M |
| 2025-06-30 | -$57M |
| 2025-03-31 | -$65M |
| 2024-09-30 | -$72M |
| 2024-06-30 | -$71M |
| 2024-03-31 | -$70M |
| 2023-09-30 | -$63M |
| 2023-06-30 | -$81M |
| 2023-03-31 | -$99M |
| 2022-09-30 | -$82M |
| 2022-06-30 | -$77M |
| 2022-03-31 | -$80M |
| 2021-09-30 | -$78M |
| 2021-06-30 | -$71M |
| 2021-03-31 | -$33M |
| 2020-09-30 | -$68M |
| 2020-06-30 | -$63M |
| 2020-03-31 | -$58M |

Source: [MarketCapTrends](https://marketcaptrends.com/company/ALLO/operating-income)